Bradley S Galer

Summary

Affiliation: Endo Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S5-12. 2004
  2. ncbi request reprint MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Clinical Development, 100 Endo Blvd, Chadds Ford, PA 19317, USA
    Pain 115:284-95. 2005
  3. ncbi request reprint Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:1455-8. 2004
  4. ncbi request reprint The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale
    Bradley S Galer
    Pain Clinical Research, University of Washington Multidisciplinary Pain Center, Seattle Washington, USA
    Clin J Pain 18:297-301. 2002
  5. doi request reprint The pain quality response profile of oxymorphone extended release in the treatment of low back pain
    Errol M Gould
    Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
    Clin J Pain 25:116-22. 2009
  6. ncbi request reprint Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S13-9. 2004
  7. ncbi request reprint Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, Chadds Ford, Pennsylvania 19317, USA
    Pain Med 4:21-30. 2003
  8. ncbi request reprint Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:296-304. 2003
  9. ncbi request reprint Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature
    Arnold R Gammaitoni
    Endo Pharmaceuticals, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:111-7. 2003
  10. ncbi request reprint Pharmacokinetics and safety of continuously applied lidocaine patches 5%
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    Am J Health Syst Pharm 59:2215-20. 2002

Detail Information

Publications25

  1. ncbi request reprint Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S5-12. 2004
    ..To determine the impact of the lidocaine patch 5% on pain qualities associated with low-back pain (LBP) through use of the Neuropathic Pain Scale (NPS)...
  2. ncbi request reprint MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Clinical Development, 100 Endo Blvd, Chadds Ford, PA 19317, USA
    Pain 115:284-95. 2005
    ..These results suggest that adding the NMDA antagonist, dextromethorphan, to opioids does not add any clinical benefit...
  3. ncbi request reprint Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:1455-8. 2004
    ..Topical lidocaine patch 5% may provide clinicians with a novel, non-systemic therapy for OA pain with a unique mechanism of action...
  4. ncbi request reprint The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale
    Bradley S Galer
    Pain Clinical Research, University of Washington Multidisciplinary Pain Center, Seattle Washington, USA
    Clin J Pain 18:297-301. 2002
    ..Several controlled clinical trials have demonstrated the efficacy and safety of the lidocaine patch 5% (LP) for the treatment of postherpetic neuralgia (PHN)...
  5. doi request reprint The pain quality response profile of oxymorphone extended release in the treatment of low back pain
    Errol M Gould
    Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
    Clin J Pain 25:116-22. 2009
    ..This study sought to evaluate the utility of assessing the multiple components of non-neuropathic pain in an analgesic clinical trial...
  6. ncbi request reprint Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S13-9. 2004
    ..e.sharp, dull)...
  7. ncbi request reprint Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, Chadds Ford, Pennsylvania 19317, USA
    Pain Med 4:21-30. 2003
    ..5- and 10-mg/acetaminophen 325-mg (Percocet) formulations in patients with low back pain (LBP) suboptimally responsive to nonsteroidal anti-inflammatory drugs, muscle relaxants, tramadol, cyclo-oxygenase-2 inhibitors, and/or prn opioids...
  8. ncbi request reprint Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:296-304. 2003
    ..This new formulation offers the combination of two analgesic drugs with complementary mechanisms of action, which results in enhanced analgesia, an "opioid-sparing" effect, and an improved side effect and safety profile...
  9. ncbi request reprint Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature
    Arnold R Gammaitoni
    Endo Pharmaceuticals, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:111-7. 2003
    ..The lidocaine patch provides a treatment option that carries a relatively low systemic adverse event and drug-drug interaction risk burden, even with continuous application of up to four patches per day...
  10. ncbi request reprint Pharmacokinetics and safety of continuously applied lidocaine patches 5%
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    Am J Health Syst Pharm 59:2215-20. 2002
    ..Mild application-site erythema occurred in most patients, but no systemic adverse reactions were judged to be related to the patches. No loss in sensation at the application site was reported...
  11. doi request reprint The dimensions of pain quality: factor analysis of the Pain Quality Assessment Scale
    Timothy W Victor
    Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
    Clin J Pain 24:550-5. 2008
    ..To provide a better empirical understanding of the dimensionality of neuropathic and non-neuropathic pain quality...
  12. doi request reprint Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale
    Arnold R Gammaitoni
    Global Center for Scientific Affairs, Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA
    Pain Med 14:526-32. 2013
    ..The aim of this study is to assess the Pain Quality Assessment Scale (PQAS) in predicting pregabalin in peripheral neuropathic pain (NP)...
  13. ncbi request reprint Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia
    Pamela S Davies
    Department of Neurology, Seattle Veterans Medical Center, Seattle, Washington, USA
    Drugs 64:937-47. 2004
    ..Because of its proven efficacy and safety profile, the lidocaine patch 5% has been recommended as a first-line therapy for the treatment of the neuropathic pain of PHN...
  14. ncbi request reprint Effectiveness and safety of lidocaine patch 5%
    Bradley S Galer
    J Fam Pract 51:867-8; author reply 868. 2002
  15. ncbi request reprint More than 7 years of consistent neuropathic pain relief in geriatric patients
    Bradley S Galer
    Arch Intern Med 163:628. 2003
  16. ncbi request reprint The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome
    Mark P Jensen
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    J Pain 7:823-32. 2006
    ..No significant differences were found between the 2 treatment conditions on any of the items. The results support the validity of the PQAS items for assessing the effects of pain treatment on pain qualities of carpal tunnel syndrome...
  17. ncbi request reprint Symptom profiles differ in patients with neuropathic versus non-neuropathic pain
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Pain 8:118-26. 2007
    ....
  18. ncbi request reprint Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning?
    Mark P Jensen
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, 98195 6490, USA
    J Pain 7:644-53. 2006
    ..These findings suggest that measures of these specific pain domains could play an important role in understanding the impact of pain on patient functioning...
  19. ncbi request reprint A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee
    Alan Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
    Clin Ther 28:352-64. 2006
    ..Oxymorphone extended release (ER) is a tablet formulation of the mu-opioid agonist oxymorphone designed to achieve a low peak-to-trough fluctuation in plasma concentrations over a 12-hour dosing period...
  20. ncbi request reprint Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale
    Mark P Jensen
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Pain 6:98-106. 2005
    ..The results support the potential utility of the NPS for assessing the patterns of changes in pain qualities that can be observed after pain treatment...
  21. ncbi request reprint Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Pain 113:9-19. 2005
  22. ncbi request reprint Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale
    Charles E Argoff
    Cohn Pain Management Center, North Shore University Hospital NYU School of Medicine, Bethpage, NY 11714, USA
    Curr Med Res Opin 20:S21-8. 2004
    ..To determine the impact of the lidocaine patch 5% on pain qualities associated with chronic pain from postherpetic neuralgia (PHN), painful diabetic neuropathy (DN), and low-back pain (LBP), using the Neuropathic Pain Scale (NPS)...
  23. ncbi request reprint Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
    Dennis C Turk
    Department of Anesthesiology, University of Washington, Seattle, WA 98195, USA
    Pain 106:337-45. 2003
    ....
  24. ncbi request reprint Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Meedicine and Dentistry, Rochester, NY 14642
    Arch Neurol 60:1524-34. 2003
    ..Continued progress in basic and clinical research on the pathophysiologic mechanisms of neuropathic pain may make it possible to predict effective treatments for individual patients by application of a pain mechanism-based approach...
  25. ncbi request reprint Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome?
    Stephen Bruehl
    Department of Anesthesiology, Vanderbilt University School of Medicine, Suite 403 G MAB, 1211 Twenty First Avenue South, Nashville, TN 37232 1557, USA
    Pain 95:119-24. 2002
    ..However, several distinct CRPS subtypes are suggested, and these could ultimately have utility in targeting treatment more effectively...